Literature DB >> 30115731

Hypertonic Saline in Bronchiolitis and Type I Error: A Trial Sequential Analysis.

Wade Harrison1, Francois Angoulvant2,3, Samantha House4,5, Vincent Gajdos6,7, Shawn L Ralston8,5.   

Abstract

: media-1vid110.1542/5799873875001PEDS-VA_2018-1144Video Abstract
BACKGROUND AND OBJECTIVES: Meta-analyses of nebulized hypertonic saline (HS) for acute viral bronchiolitis have yielded disparate conclusions. Trial sequential analysis (TSA) is a novel method designed to account for potential sources of error in conventional meta-analysis. We sought to use TSA to determine if the existing literature base is sufficient to draw firm conclusions about the effectiveness of HS in bronchiolitis.
METHODS: We used the cohort of studies identified in previously published conventional meta-analyses. Included studies were those in which authors compared treatment with HS versus normal saline (or supportive care) in children with bronchiolitis to reduce hospital length of stay (LOS) or hospitalizations. TSA results are used to provide a required information size and monitoring boundaries for statistical significance.
RESULTS: For the LOS outcome, 17 studies including 1866 patients analyzed in which authors used conventional meta-analysis reveal a statistically significant benefit (mean difference = -0.41 days; 95% confidence interval = -0.07 to -0.75); however, TSA suggests that those conclusions are premature because of failure to reach the adequate information size of 2665 individuals. For the risk of hospitalization outcome, 8 studies including 1728 patients analyzed in which authors used conventional meta-analysis reveal a reduction in the relative risk of hospitalization (relative risk = 0.86; 95% confidence interval = 0.76 to 0.98); however, TSA suggests these conclusions are premature because of failure to reach the adequate information size of 4770. Both LOS and hospitalization results from conventional meta-analysis would be considered potentially false-positives by TSA.
CONCLUSIONS: TSA reveals that concluding benefit from HS for children with bronchiolitis potentially represents type I error.
Copyright © 2018 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30115731     DOI: 10.1542/peds.2018-1144

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

1.  Bronchiolitis clinical practice guidelines implementation: surveillance study of hospitalized children in Jordan.

Authors:  Samah Awad; Rawan Hatim; Yousef Khader; Mohammad Alyahya; Nada Harik; Ahmad Rawashdeh; Walaa Qudah; Ruba Khasawneh; Wail Hayajneh; Dawood Yusef
Journal:  Multidiscip Respir Med       Date:  2020-10-09

2.  Nebulized hypertonic saline 3% for 1 versus 3 days in hospitalized bronchiolitis: a blinded non-inferiority randomized controlled trial.

Authors:  Gaëlle Beal; Catherine Barbier; Sophie Thoret; Amandine Rubio; Mathilde Bonnet; Roseline Mazet; Anne Ego; Isabelle Pin
Journal:  BMC Pediatr       Date:  2019-11-08       Impact factor: 2.125

3.  Using Trial Sequential Analysis for estimating the sample sizes of further trials: example using smoking cessation intervention.

Authors:  Ravinder Claire; Christian Gluud; Ivan Berlin; Tim Coleman; Jo Leonardi-Bee
Journal:  BMC Med Res Methodol       Date:  2020-11-30       Impact factor: 4.615

4.  Hypertonic saline jet nebulization breathing treatments produce a predictable quantity of aerosolized sodium chloride for inhalation.

Authors:  Martin J Flores; MaTais Caldwell; Kalysa D Passmore; Megan Denney; James M Carr; Kerri Carr; Jeremy M Carr
Journal:  Can J Respir Ther       Date:  2022-02-08

Review 5.  Rational use of mucoactive medications to treat pediatric airway disease.

Authors:  R S N Linssen; J Ma; R A Bem; B K Rubin
Journal:  Paediatr Respir Rev       Date:  2020-06-16       Impact factor: 2.726

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.